Ordering
Available Variants10 mg
CHA.14307-10mg
Price
€92.80
Available – Dispatch in 14 days
50 mg
CHA.14307-50mg
Price
€393.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.14307-10mg | €92.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.14307-50mg | €393.60 |
≥98% (HPLC), GPIIb/IIIa antagonist, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C35H49N11O9S2 · xC2H4O2 |
|---|---|
| CAS Number | 881997-86-0 |
| Molecular Weight | 831.96 (free base basis) |
| UNSPSC Code | 51111800 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Eptifibatide acetate, with a chemical identifier of CAS 881997-86-0, is a synthetic cyclic peptide that functions as a potent antiplatelet drug. It operates by selectively and reversibly inhibiting the glycoprotein IIb/IIIa receptor on human platelets, thereby preventing fibrinogen binding and subsequent platelet aggregation. This mechanism of action is crucial in the management of acute coronary syndrome, including unstable angina and non-ST-segment elevation myocardial infarction. Eptifibatide acetate is administered intravenously, allowing for rapid onset of action, which is essential in the acute setting of these conditions. Its short half-life also permits quick reversal of its effects if necessary, making it a valuable tool in clinical settings where precise control over platelet function is required to balance the risk of thrombosis against the risk of bleeding. This pharmacological profile supports its use in percutaneous coronary interventions.
